Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.90 |
| ▸ | MLNR | O43193 | 1/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.88 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.88 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.88 |
| ▸ | HTR2A | P28223 | 1/20 | 0.88 |
| ▸ | HTR2B | P41595 | 1/20 | 0.88 |
| ▸ | MTOR | P42345 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascomycin SCHEMBL14113233 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL386168 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL17721321 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL2390057 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL25512 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL10262882 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL13492308 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL439467 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL22409504 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL452381 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0753297-B1 | LOTION | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | claimed |
| EP-0474126-B1 | Ointments containing tricyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | claimed |
| EP-0753297-A1 | LOTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-15 | — | — | EP | claimed |
| EP-0483842-B1 | Pharmaceutical compositions containing tricyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-12-14 | — | — | EP | claimed |
| EP-0484936-B1 | Suspensions containing tricyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-10-05 | — | — | EP | claimed |
| EP-0475994-B1 | MACROLIDES FOR THE TREATMENT OF REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASES | FISONS PLC (GB) | 1994-09-14 | — | — | EP | claimed |
| EP-0484936-A1 | Suspensions containing tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-13 | — | — | EP | claimed |
| US-20230218589-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF A SKIN CANCER OR SKIN PRECANCER | UNIQUEST PTY LTD (AU) | 2023-07-13 | — | — | US | disclosed |
| EP-4161510-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF A SKIN CANCER OR SKIN PRECANCER | UNIQUEST PTY LTD (AU) | 2023-04-12 | — | — | EP | disclosed |
| US-8101650-B2 | Method for treating a immunology-related disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8067396-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-A1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | Sankyo Company, Limited (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-0851753-B1 | AEROSOL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-0753297-B1 | LOTION | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0943327-A1 | MEDICINAL COMPOSITION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-22 | — | — | EP | disclosed |
| EP-0474126-B1 | Ointments containing tricyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-19 | — | — | EP | disclosed |
| EP-0753297-A1 | LOTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0184162-B1 | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218589-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF A SKIN CANCER OR SKIN PRECANCER | FKBP1A, FKBP4, FKBP2 | FKBP1A 1/4885FKBP4 2/4885MEN1 1014/4885 |
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | FKBP1A 980/4885FKBP4 1313/4885MEN1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.